Status:
COMPLETED
Predicting Functional Outcome and Response to Therapy of Anti-NMDAR Encephalitis at Diagnosis
Lead Sponsor:
Erasmus Medical Center
Conditions:
Anti-NMDA (N-Methyl D-Aspartate) Receptor Encephalitis
Eligibility:
All Genders
Brief Summary
The goal of this international cohort study is to develop a prediction model for long-term outcome and response to first-line immunotherapy of anti-NMDAR Encephalitis, already at the moment of diagnos...
Detailed Description
Anti-NMDARE is a severe, but treatable neurological condition, with considerable and variable long-term disability. The previously developed anti-NMDAR Encephalitis One-Year Functional Status (NEOS) s...
Eligibility Criteria
Inclusion
- Diagnosed with anti-NMDAR encephalitis (according to the Graus criteria)
Exclusion
- Preceding Herpes Simplex encephalitis
- Premorbid dependency (modified Rankin Scale \> 2)
Key Trial Info
Start Date :
December 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2024
Estimated Enrollment :
714 Patients enrolled
Trial Details
Trial ID
NCT06023160
Start Date
December 1 2020
End Date
July 1 2024
Last Update
March 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Erasmus Medical Center
Rotterdam, Netherlands